Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4957978 | 0.97 | — | — | |
| SCHEMBL6958212 | 0.92 | OPRD1 (0.35) | OPRD1ADRA2AADRA2BADRA2CHRH3 | |
| SCHEMBL88222 | 0.91 | — | — | |
| SCHEMBL1489209 | 0.91 | — | — | |
| SCHEMBL3970107 | 0.91 | OPRD1 (0.41) | OPRD1ADRA2AADRA2BADRA2CHRH3 | |
| SCHEMBL6692977 | 0.91 | OPRD1 (0.41) | OPRD1ADRA2AADRA2BADRA2CHRH3 | |
| SCHEMBL290880 | 0.91 | — | — | |
| SCHEMBL327601 | 0.91 | OPRD1 (0.41) | OPRD1ADRA2AADRA2BADRA2CHRH3 | |
| SCHEMBL1081392 | 0.88 | HRH3 (0.39) | OPRD1ADRA2AADRA2BADRA2CHRH3 | |
| SCHEMBL486492 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969340-B2 | Methods for treating chronic pelvic pain syndrome | NORTHWESTERN UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130303530-A1 | METHODS FOR TREATING CHRONIC PELVIC PAIN SYNDROME WITH ANTIBODIES THAT BINDS MCP-1 OR MIP-1A | NORTHWESTERN UNIVERSITY (US) | 2013-11-14 | — | — | US | disclosed |
| US-8481035-B2 | Methods for treating chronic pelvic pain syndrome with antibodies that binds MCP-1 or MIP-1A | NORTHWESTERN UNIVERSITY (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110014205-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC PELVIC PAIN SYNDROME | MOMENTIVE PERFORMANCE MATERIALS INC. | 2011-01-20 | — | — | US | disclosed |
| US-7776884-B2 | Cyclic derivatives as modulators of chemokine receptors activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-17 | — | — | US | disclosed |
| US-7696205-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-7572813-B2 | Cyclic amide derivative as monocyte chemotactic protein modulator; prevention and treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma; antiinflammatory agents; N-[2-[[(cis) -2-[[1- (4-Chlorophenyl)ethyl]amino]cyclohexyl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-7468440-B2 | Malonamides and malonamide derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-23 | — | — | US | disclosed |
| US-7449493-B2 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMACEUTICAL COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-7381738-B2 | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-20050227960-A1 | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-13 | — | — | US | disclosed |
| US-20050192276-A1 | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-01 | — | — | US | disclosed |
| US-20040235835-A1 | Malonamides and malonamide derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
| US-20040186143-A1 | Lactams as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-23 | — | — | US | disclosed |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-23 | — | — | US | disclosed |
| US-20040110736-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT (US) | 2004-06-10 | — | — | US | disclosed |
| US-6706712-B2 | RHEUMATIC DISEASES, MULTIPLE SCLEROSIS, ASTHMA, ANTICHOLESTEROL AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-16 | — | — | US | disclosed |
| US-20030216434-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-20 | — | — | US | disclosed |
| US-20030060459-A1 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-03-27 | — | — | US | disclosed |
| US-20030004151-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192276-A1 | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity | CCR1, CCR2, BDKRB1 | OPRD1 547/4885ADRA2A 228/4885ADRA2B 153/4885 |
| US-20040235835-A1 | Malonamides and malonamide derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | OPRD1 1974/4885ADRA2A 1545/4885ADRA2B 1491/4885 |
| US-20040110736-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | OPRD1 1118/4885ADRA2A 627/4885ADRA2B 384/4885 |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | OPRD1 1225/4885ADRA2A 623/4885ADRA2B 419/4885 |
| US-20030004151-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | OPRD1 1118/4885ADRA2A 627/4885ADRA2B 384/4885 |
| US-20040186143-A1 | Lactams as modulators of chemokine receptor activity | CCL11, CCR1, CXCR1 | OPRD1 1526/4885ADRA2A 1615/4885ADRA2B 1347/4885 |
| US-20130303530-A1 | METHODS FOR TREATING CHRONIC PELVIC PAIN SYNDROME WITH ANTIBODIES THAT BINDS MCP-1 OR MIP-1A | CCR1, CCR2, CCL2 | OPRD1 63/4885ADRA2A 187/4885ADRA2B 396/4885 |
| US-20050227960-A1 | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity | CCR1, CCR2, CCR10 | OPRD1 485/4885ADRA2A 100/4885ADRA2B 92/4885 |
| US-20110014205-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC PELVIC PAIN SYNDROME | CCR2, CCR1, CCL2 | OPRD1 73/4885ADRA2A 198/4885ADRA2B 402/4885 |
| US-20030060459-A1 | Diamines as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | OPRD1 1502/4885ADRA2A 903/4885ADRA2B 703/4885 |
| US-20030216434-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCR1, CCL11, CXCR1 | OPRD1 1070/4885ADRA2A 831/4885ADRA2B 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.